诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

未开盘 03-31 16:08:25

13.560

-0.100

-0.73%

最高14.150	最低13.500	成交量944.73万
今开13.670	昨收13.660	日振幅4.76%
总市值238.93亿	流通市值202.59亿	总股本17.62亿
成交额1.30亿	换手率0.63%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.56,"timestamp":1774944505008,"preClose":13.66,"halted":0,"volume":9447314,"delay":0,"changeRate":-0.007320644216691043,"floatShares":1494000000,"shares":1762000000,"eps":0.42732418675633727,"marketStatus":"未开盘","change":-0.1,"latestTime":"03-31 16:08:25","open":13.67,"high":14.15,"low":13.5,"amount":129907623,"amplitude":0.047584,"askPrice":13.56,"askSize":3000,"bidPrice":13.55,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.42732418675633727,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775007000000},"marketStatusCode":0,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":13.66,"openAndCloseTimeList":[[1774920600000,1774929600000],[1774933200000,1774944000000]],"volumeRatio":0.8843674328335073,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":27.02,"timestamp":1774940400000,"preClose":27.09,"halted":0,"volume":18507300,"delay":0,"premium":"-55.94"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2623281397","title":"3月30日诺诚健华涨7.08%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623281397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623281397?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:26","pubTimestamp":1774859203,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日诺诚健华涨7.08%创60日新高，收盘报27.09元，换手率9.07%，成交量24.33万手，成交额6.52亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值3.126，较上一交易日上涨6.93%，近一年上涨22.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09969","688428","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623947623","title":"高盛：微升诺诚健华(09969)目标价至19.93港元 上季奥布替尼销售稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623947623","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623947623?lang=zh_cn&edition=full","pubTime":"2026-03-30 15:23","pubTimestamp":1774855423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，诺诚健华去年第四季奥布替尼销售额为3.9亿元人民币，同比增长27%，2025年销售额同比升41%，符合公司之前的指引。该行维持对诺诚健华H股的“买入”评级，将目标价由19.91港元微升至19.93港元。该行基于诺诚健华的最新业绩，将2026至28财年的净利润预测分别下调2,900万元、6,300万元及7,000万元人民币，以反映研发开支因扩展技术平台而有所上升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","09969","00512","LU1961090484.USD","LU2476274308.USD","LU2399975544.HKD","BK1191","LU0417516571.SGD","09926","09995","LU0417516738.SGD","LU0348825331.USD","LU1064130708.USD","BK1583","LU1720050803.USD","LU1969619763.USD","LU2488822045.USD","LU1794554557.SGD","LU0348783233.USD","LU0417516902.SGD","IE00B543WZ88.USD","06978","LU0348767384.USD","LU2476274720.SGD","LU1064131003.USD","LU0561508036.HKD","BK1587","BK1161","LU2328871848.SGD","LU0348766576.USD","IE00BPRC5H50.USD","LU0540923850.HKD","LU2148510915.USD","00013","LU2778985437.USD","LU0348784397.USD","BK1588","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348735423.USD","688331","BK0239","BK1574","02096","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155113111","title":"异动解读 | 创新药行业利好频传，诺诚健华盘中大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1155113111","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155113111?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:10","pubTimestamp":1774836647,"startTime":"0","endTime":"0","summary":"诺诚健华今日盘中大涨5.34%，引起了市场的广泛关注。消息面上，国家药监局发布数据显示，今年前三个月我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。同时，2026年已批准10款创新药，其中8款为国产，表明我国创新药产业取得历史性突破，保持了良好的发展势头和潜力。这一系列行业利好消息提振了市场对整个创新药板块的信心。在此背景下，港股创新药概念股今日逆市活跃，诺诚健华作为板块内重要公司之一，股价随之跟涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2e01cbc0eb24c402eed6076bf7c5c222","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184490371","title":"港股异动 | 创新药板块午后拉升，昭衍新药涨超13%，石药集团涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184490371","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184490371?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:05","pubTimestamp":1774587950,"startTime":"0","endTime":"0","summary":"信达生物涨超7%，君实生物、诺诚健华涨超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b241a979bfd22b774f426314475f336","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","06127","01093","09969","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143726488","title":"异动解读 | 诺诚健华发布强劲年报，盘中大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143726488","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143726488?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:09","pubTimestamp":1774577352,"startTime":"0","endTime":"0","summary":"诺诚健华今日盘中股价大幅上涨5.08%，市场表现强劲。消息面上，公司此前发布的2025年年度报告显示业绩表现优异，是推动股价上涨的主要原因。报告期内，公司实现营业总收入23.75亿元，同比大幅增长135.27%；归母净利润达到6.42亿元，同比扭亏为盈，增幅高达245.81%。其中，第四季度业绩尤为亮眼，单季度归母净利润同比飙升527.84%。公司2025年首次实现年度盈利，其A股股票亦因此取消特别标识。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622222894","title":"诺诚健华（688428）2025年年报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622222894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622222894?lang=zh_cn&edition=full","pubTime":"2026-03-27 06:07","pubTimestamp":1774562825,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诺诚健华发布2025年年报。截至本报告期末，公司营业总收入23.75亿元，同比上升135.27%，归母净利润6.42亿元，同比上升245.81%。本报告期诺诚健华盈利能力上升，毛利率同比增幅6.57%，净利率同比增幅160.46%。经营活动产生的现金流量净额变动幅度为122.95%,原因:药品销售收入增加及收到授权许可款项。公司奥布替尼2025年第四季度药品销售收入保持环","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700008396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622585826","title":"诺诚健华（688428）披露2025年年度报告，3月26日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622585826","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622585826?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:16","pubTimestamp":1774516613,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，诺诚健华报收于24.29元，较前一交易日下跌0.08%，最新总市值为428.63亿元。该股当日开盘25.0元，最高25.5元，最低24.15元，成交额达4.49亿元，换手率为6.8%。公司于近日披露《诺诚健华医药有限公司2025年年度报告》。公告显示，公司2025年实现营业收入23.75亿元，同比增长135.27%；归属于上市公司股东的净利润为6.42亿元，同比扭亏为盈；经营活动产生的现金流量净额为8390.14万元。公司2025年度不进行利润分配，母公司存在未弥补亏损-30.31亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600031012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","BK1161","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622832779","title":"瑞银：降诺诚健华(09969)目标价至19.8港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622832779","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622832779?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:59","pubTimestamp":1774511979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，基于去年下半年业绩，下调诺诚健华2026及2027年销售预测，并上调开支预测，导致2026及27年每股盈利预测由0.06元及0.22元，下调至0.04元及0.20元。目标价由21.1港元下调至19.8港元，维持“买入”评级。诺诚健华去年下半年收入及纯利分别为16亿元人民币(下同)及6.73亿元，大致符合初步业绩。研发开支同比增长16.9%至9.52亿元，占产品销售比例由81%降至66%。该行称，诺诚健华今年指引略逊预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106461123","title":"异动解读 | 业绩扭亏为盈且研发突破，诺诚健华盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106461123","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106461123?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:02","pubTimestamp":1774494173,"startTime":"0","endTime":"0","summary":"诺诚健华今日盘中股价大涨5.02%，引起市场广泛关注。消息面上，公司于前一交易日盘后发布了2025年年度报告，业绩表现亮眼。报告显示，诺诚健华2025年实现营业收入23.75亿元，同比增长135.27%；归属于上市公司股东的净利润为6.42亿元，成功实现扭亏为盈。此外，公司第四季度单季净利润同比大幅增长527.84%。同时，公司A股股票将于近期取消特别标识“U”。这些积极的业绩与研发进展，共同提振了市场信心，推动了股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622205220","title":"诺诚健华(09969)：练少娥获委任为公司秘书、授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2622205220","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622205220?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:08","pubTimestamp":1774436925,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，李谢佩珊女士已提请辞任公司的公司秘书，并就香港联合交易所有限公司证券上市规则第3.05条而言，不再担任公司的授权代表;及根据公司条例(香港法例第622章)第16部规定，不再担任公司于香港接收送达法律程序文件及通知的法定代表(法律程序代理人)，自2026年3月25日起生效。此外，练少娥女士已获委任为公司秘书、授权代表及法律程序代理人，自2026年3月25日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622302709","title":"诺诚健华(09969)公布2025年业绩 税后利润约6.44亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2622302709","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622302709?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:00","pubTimestamp":1774436401,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布2025年业绩，收益约23.75亿元，同比增长135.27%;税后利润约6.44亿元，同比扭亏为盈;经调整利润约6.75亿元，同比扭亏为盈。公告称，收益增长主要是由于药物销售的强劲增长，以及与Zenas Biopharma及Prolium合作所产生的许可收益。药物收益同比增加43.4%至14.424亿元，是由于奥布替尼持续的高增长，以及坦昔妥单抗于2025年第四季度上市。公司首次实现扭亏为盈，达成重要里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK1161","688428","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137613468","title":"诺诚健华2025年由亏转盈 贸易往来规模显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1137613468","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137613468?lang=zh_cn&edition=full","pubTime":"2026-03-25 18:57","pubTimestamp":1774436268,"startTime":"0","endTime":"0","summary":"2025年度，公司股东应占年内利润为人民币千元642,467，而2024年度则为人民币千元。贸易应付款项方面，2025年末合计人民币千元183,699，较2024年的人民币千元128,363有所上升。其中，在2025年末，一年内到期的应付款项为人民币千元174,206，一年至两年为人民币千元6,848，两年至三年为人民币千元2,420，三年及以上则为人民币千元185；而2024年对应时期的数值分别为人民币千元111,795、13,457、2,990及121。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621799324","title":"每周股票复盘：诺诚健华（688428）将召开2025年年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2621799324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621799324?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:38","pubTimestamp":1774118291,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，诺诚健华报收于23.69元，较上周的23.26元上涨1.85%。本周，诺诚健华3月20日盘中最高价报24.75元。本周关注点公司公告汇总：诺诚健华将于2026年3月26日召开2025年年度业绩说明会。公司公告汇总诺诚健华医药有限公司将于2026年3月26日上午11:00-12:00通过上海证券交易所上证路演中心以网络互动方式召开2025年年度业绩说明会，介绍公司年度经营成果及财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK0239","BK1161","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620734334","title":"诺诚健华（688428）披露召开2025年年度业绩说明会公告，3月17日股价上涨1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620734334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620734334?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:19","pubTimestamp":1773757158,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，诺诚健华报收于23.84元，较前一交易日上涨1.27%，最新总市值为420.69亿元。该股当日开盘23.55元，最高24.52元，最低23.31元，成交额达2.33亿元，换手率为3.62%。近日，诺诚健华医药有限公司发布关于召开2025年年度业绩说明会的公告。公告显示，公司将于2026年3月26日上午11:00-12:00通过上海证券交易所上证路演中心以网络互动方式召开2025年年度业绩说明会，介绍公司年度经营成果及财务状况。说明会后可通过该平台查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700041967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620414204","title":"港股异动 | 诺诚健华(09969)早盘涨超5% 自研VAV1分子胶降解剂ICP-538完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620414204","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620414204?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:08","pubTimestamp":1773716898,"startTime":"0","endTime":"0","summary":"诺诚健华(09969)早盘涨超5%，截至发稿，涨3.41%，报12.42港元，成交额5455.45万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260317/20260317110839_40999.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260317/20260317110839_40999.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1574","BK4588","BK0239","BK4585","688428","09969","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619458991","title":"诺诚健华宣布中国首款获批临床的VAV1分子胶降解剂ICP-538完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458991","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619458991?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:07","pubTimestamp":1773648443,"startTime":"0","endTime":"0","summary":"3月16日，诺诚健华医药有限公司（以下简称“诺诚健华”）宣布，中国首款、全球第二款进入临床的VAV1分子胶降解剂ICP-538完成首例受试者给药。ICP-538是诺诚健华自主研发的新型口服高效、高选择性靶向VAV1的特异性分子胶降解剂，VAV1是T细胞和B细胞受体下游的关键蛋白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673100474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","BK1161","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618129130","title":"诺诚健华（688428）披露董事会将于近日召开以审议2025年全年业绩，3月12日股价下跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618129130","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618129130?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:37","pubTimestamp":1773326232,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，诺诚健华报收于23.13元，较前一交易日下跌1.15%，最新总市值为408.16亿元。该股当日开盘23.4元，最高23.58元，最低22.93元，成交额达1.42亿元，换手率为2.28%。诺诚健华于近日披露公告，公司董事会宣布将于2026年3月25日举行会议，考虑及批准本公司及其附属公司截至2025年12月31日止之全年业绩及其发布。董事会成员包括崔霁松博士、赵仁滨博士、施一公博士、谢榕刚先生、胡兰女士、董丹丹博士及管坤良教授。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200038998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618928493","title":"诺诚健华：公司预计2025年度首次实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928493","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618928493?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:36","pubTimestamp":1773236199,"startTime":"0","endTime":"0","summary":"证券日报网讯3月11日，诺诚健华在互动平台回答投资者提问时表示，根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿元左右。公司对于未来包括奥布替尼在内的药品销售、管线进展及商业化合作充满信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113669094746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","688428","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618686908","title":"每日卖空追踪 | 诺诚健华 03月11日卖空量成交10.1万股，卖空比例为2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618686908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618686908?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217843,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间03月11日，跌2.96%，卖空量成交10.1万股，较上一交易日减少84.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163632a460b8dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163632a460b8dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.1262},{"period":"1month","weight":0.1216},{"period":"3month","weight":0.1024},{"period":"6month","weight":-0.2825},{"period":"1year","weight":0.4836},{"period":"ytd","weight":0.1024}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0692},{"period":"3month","weight":-0.0329},{"period":"6month","weight":-0.0916},{"period":"1year","weight":0.0722},{"period":"ytd","weight":-0.0329}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}